kras mutation and glutathion Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex Frontiers | KRAS mutation: The
Frontiers KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site specific metastasis by stimulating glutathione synthesis: Cell Reports KRAS mutation: from undruggable to druggable in cancer Signal Transduction and Targeted Therapy Uncovering new therapeutic targets for a common KRAS mutation behind cancer
Pay in 4 interest-free payments of $5.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8



